

Children with Cancer UK

Trustees' Report and Financial Statements
for the year ended 31 December 2019



Children with Cancer UK in numbers

Research - We're committed to finding cures and kinder treatments for children and young people with cancer

£3.3M invested into vital, life-saving research

32 new research awards

2 Scientific Conferences

£250K for 1 clinical PhD studentship

Supporting families – We help children with cancer and their families through the hardships of a cancer diagnosis

240 families attended our amazing days out

£280K to fund the Beads of Courage UK oncology programme

£288K towards free family accommodation close to hospitals

Awareness – We shine a spotlight on the impact of cancer on children and young people and their families

22M people have seen our social media pages

2Bn media reach

1 garden at BBC Gardeners' World Live

6 videos made to help families celebrate the end of treatment

CHILDREN WITH CANCER UK

TRUSTEES' ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2019

Olivia, pictured on the front cover, ringing the End of Treatment Bell at Birmingham Children's Hospital

TRUSTEES' ANNUAL REPORT

MESSAGE FROM THE FOUNDER AND CHAIR OF CHILDREN WITH CANCER UK	5
OUTCOMES IN 2019	7
RESEARCH OUTCOMES IN 2019	8-11
SUPPORTING FAMILIES IN 2019	12-16
AWARENESS ACTIVITIES IN 2019	17-20
FUNDRAISING	21-25
THANK YOU	25-26
FINANCIAL REVIEW	27-39
STRATEGIC PLANS	30-33
REFERENCE AND ADMINISTRATION	40-41
STATEMENT OF TRUSTEES' RESPONSIBILITIES	42
INDEPENDENT AUDITORS' REPORT	43-45
CONSOLIDATED FINANCIAL STATEMENTS	46-48
NOTES TO THE FINANCIAL STATEMENTS	49-68

MESSAGE FROM THE FOUNDER AND CHAIR OF CHILDREN WITH CANCER UK

Welcome to our Annual Report and Accounts for 2019. It's been another exciting year for the charity, with investments into a broad range of vital research and projects that have enabled us to reach more children and young people affected by cancer.

Understanding the causes of childhood cancer so that fewer children and young people receive life-changing diagnoses is a personal passion of mine, having lost two children to cancer within months of each other. Following our 2018 grant call of £2.5m for projects investigating causes and prevention of childhood cancer, I'm pleased to announce that in 2019, we awarded nine new grants in this area. These projects will look into the impact of environmental factors such as pollution and exposure to radiation on childhood cancer.

Survival rates for the most common type of childhood cancer – acute lymphoblastic leukaemia (ALL) – have significantly risen during the charity's existence. Today, thanks to sustained investment in research and improvements in treatments, in which Children with Cancer UK has had particular impact, survival rates for young patients with ALL is over 90%.

2019 marked an important step forward in treatment for previously incurable relapsed acute lymphoblastic leukaemia (ALL). A trial using CAR T-cell therapy that started in June 2016 and was jointly funded by Children with Cancer UK and Great Ormond Street Hospital Children's Charity, bore promising results just three years later. CAR T-cell therapy is a highly complex and innovative new treatment which harnesses the patient's own immune cells to treat their condition. This has led to more targeted, more effective and ultimately less harmful treatments for children and young people. The trial was so successful, that in 2019 the therapy was approved for use by the NHS for relapsed or refractory ALL in people up to the age of 25 years. This is a shining example of how research really does save lives.

Whilst this is incredible news for children and young people diagnosed with ALL, the outlook sadly isn't as positive across the wide spectrum of childhood cancers. For bone cancers such as osteosarcoma, survival rates sit at 65% and brain and spinal tumours – the most common type after ALL – claim more lives than any other childhood cancer.

In light of this, our 2019 research funding has also focused on harder to treat and rarer types of cancers, to bring hope to children and young people faced with less promising diagnoses. We pledged £1m for research into brain and spinal tumours and partnered with Bone Cancer Research Trust to host an osteosarcoma symposium that brought together world leading experts to share learnings and promote collaboration. We will continue to dedicate resource to and raise awareness of harder to treat cancers, building it into our long-term strategy moving forward.

Alongside our dedication to funding high quality research, we are committed to supporting children and their families through the hardships of a cancer diagnosis. 2019 saw the advent of an exciting partnership with Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey. You can read more about the programme and its positive impact on the mental health and wellbeing of young cancer patients on page 12.

We also granted £288k to Ronald McDonald House Charities, which provides free accommodation near hospitals so that families can stay close to their children during treatment. Our funds will be used to build a Day Room in their home at Oxford Children's Hospital which will provide respite for family and friends away from the clinical hospital environment. You can find more about what this room will offer families on page 13.

Lastly, 2019 saw the publication of our Impact Report – a culmination of independent research by The King's Fund, which was commissioned as part of our 30th anniversary celebrations in 2018. I was immensely proud to read about Children with Cancer UK's vital role in pioneering research that has gone on to save and improve thousands of young lives. You can read the full report on our website.

It goes without saying that our impact in 2019 and indeed our 32 years' history could not have been made without the generosity of our valued supporters. Thanks to their help, more children and young people are ringing the end of treatment bell and returning home to their families.

At the time of writing this foreword, we are in the midst of the COVID-19 pandemic, which has thrown the world into a period of uncertainty and instability. This will have an undeniable impact on our charity, with an estimated 40% of our income under threat. What concerns me most however, is the added pressure this pandemic is placing on children with cancer and their families. Whilst the world's attention is understandably consumed by the virus, 12 children and young people are still being diagnosed with cancer every day in the UK. Many of these children are in the vulnerable high risk group and face uncertainty around their treatment.

We want to ensure that during these worrying times, we can continue to fund life-saving research and essential support services to give hope to children with cancer and their families. I would like to pay tribute to our staff who adapted immediately to working from home, which we implemented on 13th March, a good 10 days in advance of the Government's decision to announce a UK-wide lockdown. I want to convey my sincerest thanks to all those who have continued to support us during these trying times.

Eddie O'Gorman OBE
Founder and Chair of Trustees

OUTCOMES IN 2019

How donations have helped children and young people with cancer.

We are pleased to announce that in 2019 we raised £17.3m to fund specialist childhood cancer research and support families.

For every £1 we spend on fundraising, we raised £4 more

For every £1 donated we spend

- 77p on fighting childhood cancer
 - 37p on research projects,
 - 15p on supporting families,
 - 25p on raising awareness,
- 23p on raising more money = £1

We receive no government funding and rely exclusively on the generosity of our supporters

OUR YEAR IN RESEARCH

We invest in vital, specialist research that would otherwise go unfunded.

In 2019, we funded 32 new research projects, worth £3.3m, to fight the injustice of cancer in children and young people. Combined with existing active research grants, this means that we are now funding a total of 69 projects, worth over £25m at centres of excellence around the UK. Our funding is helping more children survive cancer.

The research we fund is aimed at understanding the causes of childhood cancer and how it can be prevented, developing new treatments which are less toxic for children, as well as finding cures for some of the hardest to treat cancers.

New research awards

In 2019, we made 32 new research awards. These ranged from large project grant funding, capacity building through our studentships and supporting specialist childhood cancer meetings. All funding applications to our research rounds are rigorously scrutinised by our Scientific Advisory Panel and reinforced by expert peer review. This ensures that we only support the highest quality research that will have the greatest impact in terms of patient care.

Here is an overview of some of the projects we've funded this year.

Improving the safety and effectiveness of CAR T-cell therapy for childhood acute myeloid leukaemia (AML), Dr Srdan Rogosic, UCL Great Ormond Street Institute of Child Health

AML is a rare condition with around 70 new cases diagnosed in children every year in the UK. Only two thirds of these children are cured, so novel therapies are urgently needed.

CAR T-cell therapy is an immune-based therapy which works by enhancing the body's own immune system to destroy cancer cells more effectively and with fewer side effects from chemotherapy drugs. It's the most promising new cancer treatment since the development of the first chemotherapies in the late 1940s.

Dr Rogosic's research will be addressing the limitations of current CAR T-cell therapies for AML to ensure that they are more effective and targeted. His team will be developing new techniques to better identify AML cells and also ensure that the therapy doesn't damage healthy cells.

If successful, this project will form the basis of a new clinical trial in children with otherwise incurable AML.

Early diagnosis of classical Hodgkin lymphoma, Professor Ruth Jarrett, University of Glasgow

Hodgkin lymphoma is one of the most common cancers in young people but diagnosis is often delayed because signs and symptoms are similar to other conditions. This may lead to avoidable illness and anxiety, as well as spread of the disease and need for more treatment.

Blood samples from almost all untreated Hodgkin lymphoma patients contain high levels of a molecule called CCL17, which has been proven to be a good predictor of Hodgkin lymphoma in young people.

The research on CCL17 has so far only been carried out in the hospital setting. Professor Jarrett's team now want to evaluate this test in the primary care setting i.e. at GP practices to encourage earlier diagnosis. This would involve a simple and cheap blood test that GPs could carry out to identify potential Hodgkin lymphoma patients presenting symptoms. Those whose test results show a high level of CCL17 would be immediately referred by their GP to hospital for further investigation.

This study will inform the design of a larger study evaluating the value of CCL17 testing for the early diagnosis of Hodgkin lymphoma in the primary care setting. It is hoped that this large study will lead to the introduction of CCL17 testing into routine healthcare, which could in turn result in less intensive treatment and reduced side effects.

Studying the relationship between folate and leukaemia risk, Professor Catherine Metayer

We don't know enough about what causes acute lymphoblastic leukaemia (ALL). Professor Metayer is studying how exactly the nutrient folate might reduce risk of the disease, and whether this varies between different people. This could lead to new ways to identify children at risk and prevent them from developing this cancer.

Folate is an essential nutrient that can be found in lots of foods. Pregnant women are advised to take folic acid supplements, a man-made version of folate. We know from previous research that pregnant women who consume lots of folate have children who are less likely to develop ALL. However, we don't know exactly why this is the case.

In this project, Professor Metayer and her team aim to find out exactly how folate affects different children's chances of developing ALL. They will do this by studying DNA to see how a child's genes affects how the body uses folate, as well as testing blood samples for chemicals produced when the body uses folate.

Working with the Childhood Cancer and Leukaemia International Consortium, the DNA in this study will come from nearly 22,000 children, around 8,000 of whom have developed ALL.

This research project will reveal new information about the link between folate and the risk of developing ALL, which could lead to new strategies to preventing the disease, for example, by identifying children who could benefit from folate supplements. This would mean fewer children having to go through cancer treatment and living with the long-term effects on their health and wellbeing.

Bringing world leading experts together

In 2019 we held conferences attended by world leading experts, to promote collaboration and shared learning for the advancement of specialist childhood cancer research.

Childhood Cancer Conference

We welcomed 125 attendees to our Childhood Cancer 2019 Conference, which was held in Newcastle in September. Twenty-four speakers addressed the topic, “exploiting genomic medicine throughout the patient journey”, providing updates on how genomic medicine is being used to deliver new therapies, reduce toxicity, enable earlier diagnosis and help efforts to prevent cancer in children, teenagers and young adults. It was chaired by Professor Steve Clifford of Newcastle University and Dr Nick Goulden, Hon. Medical Director of Children with Cancer UK.

Our keynote speaker was Newcastle’s MP and Shadow Minister (Business, Energy, Industrial Strategy) Chi Onwurah. She gave strong support for our drive to encourage the development of innovative personalised medicine based on genetic profiling which will greatly improve treatment outcomes.

We had encouraging updates on our precision medicine project (SMPaeds) and on the multi-centre INSTINCT programme that we support and whose aims match the conference theme.

We core-fund SMPaeds which aims to carry out detailed genomic and proteomic profiling of every paediatric solid tumour within two weeks of initial diagnosis. This is a pilot of what we hope will be developed and integrated into standard NHS practice. The extra detail is essential to enable personalised treatment to help maximise cure and minimise adverse side effects.

The INSTINCT research programme integrates high risk paediatric brain tumour research at The Institute of Child Health, Newcastle University and The Institute of Cancer Research, with the aim of creating a concerted clinical/research network to deliver improved therapies for children. Many key researchers and clinicians associated with the INSTINCT programme gave individual talks on their work and Professor Steve Clifford gave an overview of progress to date and hopes for the next stage, INSTINCT2, which should start by 2021.

International Osteosarcoma Research Symposium

In January 2019, Children with Cancer UK, in partnership with Bone Cancer Research Trust, held the first International Osteosarcoma Research Symposium. The event was held in memory of 11-year-old Frankie Biggs who sadly passed away from the disease.

Osteosarcoma is the most common type of childhood bone cancer and usually develops in the long bones of the arms or legs. It has amongst the lowest survival rates of all childhood cancers. Overall five-year survival rates for osteosarcoma remain at just 65% and it has now been identified as a priority by the National Cancer Research institute.

This symposium brought together researchers from across the globe to identify current research progress and challenges in order to identify opportunities to move research forward. The day was opened by Alison Biggs, Frankie's mother, and close family friend, Paul Britton, who shared their moving and emotional story.

Following the success of this symposium, Children with Cancer UK and Bone Cancer Research Trust announced their new partnership in Frankie's memory to advance research into osteosarcoma. We are grateful to the Trustees of the Britton Family Foundation for their generous grant to support this vital event and to the Bone Cancer Research Trust for their support in the organisation and delivery of this symposium.

Frankie's story

"Frankie developed a limp when he was nine years old and we were told by four different doctors that it was ligament damage. We eventually took him to A&E and following an X-Ray he was diagnosed with osteosarcoma.

It had broken his knee cap in half and spread round his little body, including both knees and lungs. My son took everything that stood in his path, from MRI scans, a bionic leg, the lower lobe of his lung being removed to eventually too many brain tumours to count.

This shouldn't be happening to children and in the two years of living and breathing cancer with my son, I also watched six other children die from this awful disease, including Frankie's girlfriend, who he met at the hospital.

Last year we celebrated what would have been his 12th birthday without him. He was my world, my hero, my best friend and my life. Cancer has changed us all, but it made my son the hero he was and still is, in my eyes, today."

Frankie's story has inspired a partnership with Bone Cancer Research Trust, resulting in the Osteosarcoma Symposium. Alongside this, we committed £500k of funding towards osteosarcoma research, with Bone Cancer Research Trust committing £450k, all to find more effective treatments for children like Frankie.

SUPPORTING FAMILIES IN 2019

We funded £918k towards projects aimed at alleviating some of the burdens a cancer diagnosis places on children with cancer and their families. We also hosted 240 families at 10 events throughout the year, giving them happy memories and a welcome respite from the daily worries cancer brings.

Beading helps healing

We partnered with Beads of Courage UK in 2019 to allow all young cancer patients being treated in the 110 children's cancer wards across the UK continued access to the Beads of Courage oncology programme.

The programme promotes positive coping strategies by helping children to visualise and articulate their experiences through a process called beading. Different beads are given to children to represent and record each step of their treatment. For example, a yellow bead represents an overnight stay in hospital, a white bead a course of chemotherapy and a glow-in-the-dark bead a course of radiation therapy. The beads join together to form often long, physical representations of a child's journey to recovery.

To mark the partnership, the first bead a child now receives is a branded Children with Cancer UK bead.

Our support in 2019 has provided approximately nine million beads to roughly 9,000 children in over 100 hospitals across the country. It has also enabled training sessions to hospital staff on how to support individual patients throughout the programme both practically and emotionally. Beads of Courage UK staff travelled over 10,000 miles to deliver training in 2019

"The beads have been a visual guide showing how far Luuk has come and what he's endured. They also show him how brave he has been throughout his journey. Luuk's incredibly proud of his beads, as am I. We talk about his journey when we thread the beads on the string – it's almost like turning the pages, getting closer to the end of this difficult chapter in his life. The beads propel him forward as his treatment progresses as they remind him that he's done it before and he can do it again." Charmaine, mum of Luuk aged 5.

“Isaac received 1,994 beads during the course of his treatment. They were such a wonderful, visual representation and were a way for him to tell his story. As each bead represents different treatments and procedures, it became a really easy way for Isaac to show what he was going through. He took his beads into school several times along the way to explain his experiences to his friends.” Liz, Isaac’s mum

“The Beads of Courage helped me to understand how much our young children go through. Seeing all the beads that they gain over the course of their treatment is astonishing. The beads help children understand what they are going through themselves. They help them feel positive and even excited when they receive another bead. Although treatment is hard for our little fighters, they have something amazing to show at the end. Beads of Courage are incredible.”

Jessica, Activities Assistant, Peterborough City Hospital

A place to recharge during difficult hospital stays

When a child is in hospital, it is common for families to experience feelings of social isolation and disruption to family routines. Many families require respite from the hospital’s clinical setting in order to recharge and sustain the energy required to meet the needs of a sick child.

We’ve long supported the provision of free accommodation near to hospitals for families whilst their child are receiving treatment. Over the years, we’ve provided £8.6m of funding towards 11 homes across the UK.

In 2019, we committed to fund a Day Room at Ronald McDonald House Oxford, which is being expanded into a new 62-bedroom house, accommodating an average of 1,000 families per year.

The Day Room is just a few minutes away from the children’s ward, meaning that family and friends can very easily move between the two. The space will be complete with a fully-equipped kitchen, dining and play areas to allow families to maintain a degree of normality, re-establish routines and share mealtimes together. Families will be offered activities such as daily coffee mornings, parent pamper days and arts and crafts sessions for siblings, which will help to relieve stress, enhance family cohesion and promote social interaction.

“We are really grateful to Children with Cancer UK for generously funding the Day Room at our new Oxford House, which is set to open Summer 2020. The new 62-bedroom house next to the Oxford Children’s Hospital will provide a much needed ‘home away from home’ accommodation for families with children undergoing treatment in Oxford Children’s Hospital. Thanks to Children with Cancer UK, the Day Room will provide the perfect place for families to rest and recharge.”

Jon Haward, Executive Director of Ronald McDonald House Charities UK

Financial Hardship Grants

On top of the devastation a cancer diagnosis brings, the financial impact of cancer can be crippling. At a time when many parents have to give up work to help care for their child, expenses on travel, food and bills increase. Research has shown that parents spend an average of £600* extra every month when their child is receiving cancer treatment, which can last for up to three years. That's why, for over a decade, we've been funding CLIC Sargent's Financial Hardship Grant programme to help alleviate the cost of cancer for families.

Our gift of £350,000 in 2019 has resulted in 1,263 grants made to families, to help with costs such as travel, hospital parking and food. These grants are lifelines for families, many of whom are struggling to make ends meet.

This year after an unexpected surge for different types of grants, a small proportion of the funding was spent on other grants to help families with the financial impact of cancer. These included 'Registration Grants' to help families cover the initial costs of cancer, 'Home Essentials Grants' to help purchase specialist equipment for children and young people diagnosed with cancer and 'Compassionate Grants', helping to alleviate the financial burden that bereavement can bring.

"I don't think people understand how much it costs, not just to live and have no job when you're young but also when your family can't always support you. You spend a lot of money. You're getting buses to hospital, then you're getting taxis when you're not well enough to get on a bus – you can't because of your immune system.

During treatment I lost two stone, so I also needed new clothes because I couldn't fit in my old ones. It's all these things that people don't think about...[the grant] made a massive difference."

Seren, who was diagnosed with cancer aged 19

*According to CLIC Sargent's to CLIC Sargent's Cancer Costs Report (2016)

Amazing days out for families affected by childhood cancer

A snapshot of our much-loved events that allow families to enjoy quality time together and a break from the daily stresses of a childhood cancer diagnosis.

Grand Pier, Weston-super-Mare

Happy childhood memories are often formed by the seaside. That's why we love putting on our annual event at the Grand Pier in Weston-super-Mare. Thirty-six families were treated to lunch and enjoyed free access to rides all day. Entertainers delighted the children with close-up magic and magnificent balloon modelling.

Showtime at Zippos Circus

Forty-seven families were wowed by a private performance at Zippos Circus. They also enjoyed a buffet lunch, an appearance by Belle from Beauty and the Beast, face painters, balloon modellers and more. This is a highlight in our events calendar and 2020 will mark 10 years of the event.

Alton Towers Adventure

A new addition to our events calendar – we invited 49 families for a VIP, adrenaline filled day at one of the UK's top theme parks. Guests enjoyed unlimited, fast track access to the rides.

A magical visit to the Harry Potter Studios

In December, 30 families were welcomed to the 'Hogwarts in the Snow' experience at Warner Bros. Harry Potter Studios for an exclusive tour. Guests had a go at flying on a broomstick, a sip of deliciously frothy Butterbeer and even received their very own personalised wands. This was also a brand new event for us.

A Christmas to remember

We hosted our first ever Christmas parties in London and Manchester for 68 families affected by childhood cancer. Guests were put into the festive spirit with gingerbread decorating, a visit from Elsa from popular Disney film Frozen and a meeting with Santa who delivered a gift to every child. Our parties also attracted celebrity support, with CBBC presenter Nigel Clarke attending our London party and actor Cel Spellman attending in Manchester. The parties also featured on local news, including BBC London and ITV Granada.

“When a child is diagnosed with the disease, it affects not just them but the whole family. This day out reminds them that they are youngsters, not just cancer patients. The annual event supports families through their difficult treatment journey. When Oliver found out he could go to the day out again he was thrilled.” Sarah, Oliver’s mum, Grand Pier event

Special thanks to the Grand Pier, Kerry Michael Zippos Circus and Cos Onisiforou for their ongoing generosity.

Lily’s story

“When we were given the news that Lily had a brain tumour, it was completely shocking and devastating but suddenly everything made sense. She had been poorly for some time, drastically losing weight, becoming very lethargic and developing flickering eyes.

After an initial 18 months of chemotherapy, we celebrated the end of treatment in May 2019. We had a four month break before discovering that the tumour had grown along with a number of cysts and that her vision had further deteriorated. A shunt was fitted because the fluid in her brain does not drain as it should due to the tumour. After further chemotherapy, Lily began to walk with a slight limp and a scan showed that the tumour and cysts had continued to grow. She will now need a further course of chemotherapy for another year.

Because of Lily’s condition, we find it very hard to think about Christmas or make any plans. We don’t know what Lily’s health will be like, whether we’ll be in a hospital room or celebrating with family. Cancer consumes everything in your life.

We attended Children with Cancer UK’s London Christmas party in December. The event was a chance for Lily to enjoy the festivities of Christmas like every child deserves and for us to have a much needed break from hospital appointments and treatment, as well as meet other families affected by childhood cancer.”

Lianna, Lily’s mum. Lily was diagnosed with an optic pathway glioma in 2017 at the age of one.

PUTTING CHILDHOOD CANCER ON THE AGENDA

Our awareness raising activities in 2019 highlighted the impact of cancer on children and young people and their families across social media, our website and via media coverage.

Digital media

- Facebook fundraiser donations grew by 31% from £464.9k in 2018 to £611.5k in 2019
- 21.9 million people saw our content across Facebook, Twitter and Instagram (up 65% in comparison to last year)
- 522,000 people engaged with our content across Facebook, Twitter and Instagram (up 66% in comparison to last year)
- 501,518 people visited our website

Making our voice heard

- TV advert had 174,694,900 views
- 1,882 print and online articles (2018 was 717) – 162% increase
- Publicity value of £2.1 million (2018 was £925.2k)
- Reach of 2 billion (749.9 million in 2018)
- Around 14 TV broadcast pieces

Our website

We are constantly evolving our website to improve the user's experience. In 2019, we revamped our website to help improve mobile experience, as 64% of our users to the site are from mobile devices. Taking a mobile-first approach to design and functionality will ensure a seamless experience across all devices, leading to better engagement and prepare the site for further growth

Engaging people with our content

In 2019, we created a wealth of new content to raise awareness of childhood cancer. Six videos, featuring different children and their families, captured the celebratory moment families affected by childhood cancer look forward to after what is often years of gruelling cancer treatment – ringing the end of treatment bell. These videos were shared on our website, social media and You Tube channels and were viewed by more than 150,000 people.

We also created two new Little Translator videos – 'What is childhood cancer?' and 'What is a childhood brain tumour?' – to explain complicated scientific content in an accessible and more engaging way. Our Little Translator videos were seen by 20,200 people.

In addition, we greatly increased our parent-led blogging content, by engaging and working with families affected by cancer to create a series of new blogs, hosted on our website. Through this

content, parents and/or children affected by cancer shared unfiltered perspectives of the realities of living with childhood cancer. More than 127,000 people viewed our blog content.

Childhood Cancer Awareness Month

In September, our campaign for Childhood Cancer Awareness Month ‘A child with cancer is not alone’ focused on the wider impact of childhood cancer – with a cancer diagnosis affecting not only the child, but the entire community around that child. We commissioned a OnePoll survey of 2,000 adults and found that almost 18% of the UK population have known a child who has suffered from cancer, and more than one in 10 have known a child who has died from the disease.

As part of this campaign, we featured the story of cancer survivor Blue, with emphasis on how his cancer impacted those around him. The campaign reached over two million people, through media coverage and our social media pages.

“It was painful and just destroys your body. It was scary, but at the same time I felt like I had someone beside me helping me fight off the cancer. And those people were my doctors and nurses, my mum, my dad, my nan, my grandad and the rest of my family,” Blue.

Blue was diagnosed with acute myeloid leukaemia (AML) in March 2011. As part of our Childhood Cancer Awareness Month campaign, Blue spoke about his experiences, his support network and life after cancer.

Chemo-free Christmas campaign

Our 2019 Christmas campaign, ‘Chemo-free Christmas’ followed families at various stages of their childhood cancer journey as they navigated the holiday period. We shared content relating to experiences of ‘Christmas with chemo’, ‘First chemo-free Christmas’ and ‘Christmas after chemo’, such as Christmas parties and a child ringing the end of treatment bell the week before Christmas. Our underlying theme was that through our research, we hope that one day every child will enjoy a chemo-free Christmas.

Media coverage of the Chemo-free Christmas campaign across broadcast, print and online had an estimated total reach of 5 million, including a piece on ITV Granada. More than 615,000 people saw our content across Facebook, Twitter and Instagram.

“Kids living with cancer have their normality ripped away from them and for any child to spend time in hospital over the Christmas period is heart-breaking and simply not fair. Mia ringing the end of treatment bell the week before Christmas, is the greatest gift we could ever wish for. We're incredibly grateful we get to spend this special time of the year like every family should be able to, without the stress of cancer treatment or hospital visits.”

Andy, Mia's dad.

The Children with Cancer UK Strength of Humanity Garden

Our garden at BBC Gardeners' World Live illustrated the impact of childhood cancer on young people and their families and was inspired by Megan Darke who lost her life to brain cancer in 2016, aged 11. Planting was used to reflect thoughts and feelings associated with childhood cancer and a sculpture in the centre of the garden of an end of treatment bell represented the happy moment when a child finishes treatment.

The garden was created by designer Ben Stubbs in collaboration with Megan's parents. Attracting 100,000 visitors, our presence at BBC Gardeners' World Live was a valuable and creative opportunity to engage with new audiences and raise vital awareness of childhood cancer. Megan's story, the garden and charity messages were featured on BBC East Midlands evening news as well as in local print and radio.

30 years of impact on children's cancer

To celebrate our 30th anniversary in 2018, we commissioned the publication of a report based on independent research undertaken by The King's Fund. This report assesses our impact to date on children's cancers and looks at how advances in cancer research and treatments have changed people's lives. The findings demonstrate the significant impact of our charity, not only in the field of childhood cancer research, but also in the offshoot family support services that are desperately needed once a child receives a diagnosis. The King's Fund identified areas in which Children with Cancer UK has had particular impact and success, some of which include the funding of life-saving and life-changing research such as the Minimal Residual Disease (MRD) test and Precision Medicine and actively promoting collaboration and campaigning across the childhood cancer 'community'.

To accompany the publication of this report, we ran a social media campaign which highlighted our stand out achievements in our 30 year history, which was seen by 70,000 people.

Suki's story

“No one ever dreams of being told the terrifying words, ‘your child has cancer.’ The first eight months were particularly tough, with regular high dose chemotherapy, blood and platelet transfusions, contracting viruses and infections; there were many admissions and hospital stays.

Suki suffered numerous side effects from treatment, including weight gain and loss, constant nausea and of course losing her hair. Despite a hard few years, Suki remained positive and in August 2019, she finally rang the end of treatment bell. It was such a huge milestone and was wonderful to see her beaming smile.

Children with Cancer UK helped fund research for the treatment Suki received. They've also provided us with memorable family days and special times with other oncology families – people we're now proud to call our friends. We are so grateful for the charity's support and everything they continue to do to make outcomes like Suki's possible.”

Rachel, Suki's mum. Suki was diagnosed with acute lymphoblastic leukaemia when she was just four years old.

We attended Suki's bell ringing and made a special video for her and her family, which you can watch here: https://www.youtube.com/watch?v=NSerq_Hun2M&t=3s

FUNDRAISING HIGHLIGHTS

A snapshot of some of your greatest achievements this year, that have helped more children with cancer ring the end of treatment bell

- 4,300 people participated in challenge events, raising an incredible £4.5m
- 1,200 runners in the 2019 Virgin Money London Marathon, raised over £3m
- Raffles raised over £1.8m
- £1.4m from 143 gifts in Wills
- Kwik Fit began fundraising against £1m pledge
- The Children with Cancer UK Ball raised £631k
- £611.5k in Facebook donations
- RS Components raised £250k from their Tour de Branch event
- Chosen as charity of the year by Ladbrokes for 3 years
- Opera at Syon raised £126k
- The Sammy Jo Brandon Foundation raised over £80k to date
- Charity Aid raised over £23k
- Anglers Against Cancer's fishing competitions raised over £220k to date
- Top Model's 2019 shows raised £26k
- 568 riders raised over £311k in the Prudential RideLondon-Surrey
- Over 300 swimmers took part in Children with Cancer UK Swim Serpentine, raising over £79k

The year of the Tour de Branch

In 2019, two of our corporate partners – Kwik Fit and RS Components – rallied together their keenest cyclists to embark on epic bike rides to their many branches across the country.

Kwik Fit

As part of the company's £1m fundraising pledge, over 1,000 Kwik Fit employees cycled over 2,500 miles in 31 days from Aberdeen to London, across to Devon and finishing in Manchester with a lap of the velodrome. Dignitaries from multiple towns came to cheer on the riders and they also met families affected by childhood cancer along the way. Actress Chizzy Akudolu and singer and actress Suzanne Shaw also supported the event, officially starting and ending the tour.

RS Components

RS Components employees travelled 1,100 miles over two weeks from Aberdeen to the Head Office in Kings Cross, raising an incredible £250k. The ride was led by Mike England, President EMEA and Olympic athlete Greg Rutherford celebrated with the riders at the end of the tour.

Helping kids kick cancer through football sponsorships

We were gifted front of shirt sponsorship for a number of football clubs thanks to our partnership with Ladbrokes and its parent company, GVC. Our logo featured on the Charlton Athletic, Sunderland, Sheffield United, Derby and Scottish League shirts for the 2019/20 season. We were also given the opportunity to create branded content around the stadiums to appear on LED perimeter boards surrounding the pitch, on the jumbo screens and in the match day programme. With clubs such as Charlton Athletic having a cumulative seasonal live TV audience of 6.2 million, this was a valuable brand awareness opportunity.

During Childhood Cancer Awareness Month in September, we invited seven children affected by cancer to walk out on pitch before the Charlton vs Leeds game with a giant gold ribbon (the universal symbol for childhood cancer), forming a guard of honour for the players to walk through.

The Children with Cancer UK Ball

The Children with Cancer UK Ball was the first event that kick-started the charity and is central to our founding story – that is of the loss to Marion and Eddie O’Gorman of their son Paul to leukaemia in 1987. The inaugural Ball was held in Paul’s memory.

2019 marked the 32nd year of the Ball and around 800 guests came together at London’s Grosvenor House Hotel to enjoy a night of entertainment and fundraising. Hosted by Irish comedian Dara Ó Briain and headlined by R&B legend Billy Ocean, this year’s Ball raised more than £600k.

A very special family was among the attendees, with seven-year-old cancer survivor Suki Corbett, who finished treatment for acute lymphoblastic leukaemia in April 2019, taking to the stage to speak about her cancer journey.

The Ball was also attended by a host of celebrities, including reality TV star Scarlett Moffatt, Loose Women’s Linda Robson, TV presenter Debbie McGee and TV and Radio personality, Vanessa Feltz.

A behind the scenes look at our research

In October, we took a group of 33 committed supporters on a lab tour at the UCL Institute of Childhood Health and invited them to hear from a researcher, family and our CEO. A chance to see the impact of their support, from inside the lab to hearing a real life account of childhood cancer, guests were encouraged to consider how leaving a gift in their Wills to Children with Cancer UK could help improve outcomes for children with cancer and their families.

The tour of the lab was led by two researchers whom we are currently funding – both are looking into better treatments for acute lymphoblastic leukaemia (ALL). Dr Owen Williams invited supporters to view leukaemic cells through a microscope and showed them what the cells look like after drug exposure. Dr. Luca Gasparoli explained what a gene-chip looks like and how this is used to examine gene expression changes in leukaemic cells. The tour was followed by a reception at One Aldwych Hotel where guests heard from our CEO and guest speaker, Andrew Heffer-Lamond, whose daughter, Daisy, was diagnosed with ALL at the age of four.

“The event showed how much our donations are needed.” Mr Robert Love
“The whole event was extremely informative and interesting...a wonderful experience not only to be able to attend, but to meet all the dedicated people who spend each working day in so many different departments and laboratories helping to treat and improve the lives of children with cancer, and their families.” Miss Ayla Turkmen

In 2019, we received £1.4m from 143 gifts in Wills. If you're interested in leaving a gift in your Will or want to find out more, visit <https://www.childrenwithcancer.org.uk/get-involved/other-ways-to-give/will/> or call us on 020 7404 0808.

Danielle's story

Danielle ran the 2019 Virgin Money London Marathon for Children with Cancer UK after her best friends' eight-year-old son was diagnosed with brain cancer.

Danielle, an emergency care support worker, was with mother, Laura, the day George was diagnosed with Medulloblastoma – the most common childhood brain tumour.

“George had headaches on and off and then started having coordination and appetite issues. One morning he collapsed and vomited; Laura took him to the hospital. That day my best friend and beautiful mum of George had the worst news any mother could possibly imagine. A growth was discovered in his brain and was later removed after an agonising 10hour operation.

A gruelling year later with significant weight loss, feeding problems, infection after infection, George had completed his radiotherapy and chemotherapy with a big smile.

Working in healthcare, my job is all about helping people and when George was diagnosed I felt completely helpless – so I decided to run the marathon and raise money for Children with Cancer UK.

The charity's focus on funding research into less aggressive treatments for childhood cancer is so important. George was really ill throughout his treatment, which was horrible to see. Although childhood cancer is different to cancer in adults, many treatments are still based on adult ones and can have devastating side effects for children.”

FUNDRAISING COMPLIANCE

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.

We will keep the donors personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donors details with other charities or sell it to businesses. Some organisations help us with our fundraising, but will only use the donors data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (updated February 2020).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Protecture, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes: call monitoring, site visits and live call listening and mystery shopping. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerately disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to the protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document '[Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.](#)'

We adhere to the [Fundraising Regulator Promise](#) ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters, which is why, in 2018, we published our [Supporter Charter](#) as a commitment to our supporters.

Our [Feedback and Complaints policy](#) was reviewed in May 2019 and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan – Dec) 2019 we received 162 complaints across all teams which is an increase on the previous year (88 complaints) but reflects a more diverse range of fundraising activities held across the year.

We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards and we will work hard to learn from our mistakes and to make sure they don't happen again. If our supporters and members of the public are unhappy with any aspect of our work we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.

THANK YOU

We are immensely grateful to all our amazing supporters and fundraisers, who helped us raise the huge total of £17.3m in 2019.

To our corporate partners:

- GVC
- Kwik Fit
- Ladbrokes
- Lockton
- RS Components

To all those who played a part in our successful fundraising events:

- Abbie Stanwix and Bella-Rose Leach
- Andrew Heffer-Lamond
- Caroline, Lucy and Michael Brown
- Caroline Randerson
- Dr. Owen Williams
- Lady Julia Craig Harvey and Mrs Peter Hargreaves-Allen, Chairs of the Opera at Syon Committee and the Committee members
- One Aldwych
- The Children with Cancer UK Ball Committee

To everyone who helped us fundraise through sporting and community events:

- Action Challenge
- Finnley's Warriors
- London Marathon Events
- Mike Levitz
- Rat Race Events
- St Baldrick's Foundation and IHS Markit
- Team Luton
- Team Torri
- The Sammy Jo Brandon Foundation
- Top Model
- Virgin Sport

To our dedicated Trustees:

- Eddie O'Gorman
- Sandra Mileham
- Linda Robson
- Alasdair Philips
- Virna Midgley
- Caroline Randerson
- Ann Amaya-Torres

All our supporters and volunteers have helped improved the lives of children with cancer and their families in 2019 – thank you.

A very special thank you goes to all the extraordinary families who have shared their experiences in 2019. Your involvement is central to our work and your help in raising awareness and vital funds to help young cancer patients is invaluable.

FINANCIAL REVIEW

Incorporating the Directors' Strategic Report and Administrative Report for Companies Act Purposes



The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31st December 2019 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

Financial review

The Consolidated Statement of Financial Activities (SOFA) set out on page 46, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

Our total income has increased from £16.8M to £17.3M, which has enabled the charity to award research and welfare funding of over £4.2M during the year. Whilst we continued to fund ground-breaking research in 2019 (£3.6M), our other focus for 2019 was supporting our Welfare projects, with over £0.5M being directly invested in this strategic pillar.

With our fundraising strategy in place for 2019, we were able to build on our established areas of fundraising and are pleased to report growth in Individual Giving, Regular Giving, Community Fundraising, Corporate and Trusts Fundraising. Sports Events continue to be an important income stream for us with income of £4.5M raised this year. Much of this income is raised through the charity purchasing places in sporting events, such as the London Marathon, and allocating these to fundraising participants.

Our continued investment in online and mainstream media has, in addition to broadening the awareness of our cause, led to sustainable growth in individual giving and regular giving. Both of these areas have seen growth during the year and provide core income streams with which we can engage with our supporters. Individual giving income of £4.4M and regular giving income of £2.1M has been received during the year, a combined increase of 30% from the previous year. We now have 35,564 regular givers through various channels which represents our higher ever total. This is an addition to the 4,178 regular players of the weekly lottery.

- 37p on research projects
- 15p on welfare projects
- 25p on raising awareness

We reinvest 23p from every £1 raised, to raise even more money.

For every £1 we spend on fundraising, we raise almost £4 more.

This Financial Review was written during the COVID-19. With many fundraising events cancelled during 2020 we have seen a drop in our fundraising income, this has been mitigated by a drop in our expenditure to host these events. We continue to monitor the situation closely and the ultimate impact of COVID-19 on the charity is yet to be seen.

Reserves

At the end of the year, the charity held £10,901,419 (2018: £10,171,622) in total reserves. £10,374,075 was held in unrestricted reserves and £527,344 (2018: £1,064,478) in restricted reserves.

The restricted funds comprise of donations that were to be spent on specific causes and projects as detailed in Note 19.

Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity's charitable purposes. It is the intention of Trustees to expend these funds as soon as possible whilst using them in a structured manner to meet their long term objectives.

The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year's grant award programme. The remainder, is set aside for fluctuations in income that could impact the charity's ability to carry out its services.

The current year's grant award programme of £4.8M leaves approximately £6.1M as a buffer. With a drop in our income due to COVID-19 expected for the current year the Trustees consider that this is a reasonable buffer to have in place as a contingency at this time.

With a focus on the changing environment due to COVID-19 the Trustees are currently reviewing the reserves policy to ensure the charity can meet both its short and long term obligations.

STRATEGIC PLANS 2020 AND BEYOND

In 2019, we began a review of our fundraising strategy and to revisit our strategic vision and mission(s) to ensure they remained true to our charitable aims and objectives.

Our vision is: A world where every child survives cancer.

To achieve this vision, we will continue with our primary mission which is to fund scientific research to:

1. better understand the causes of childhood cancer.
2. find kinder and safer treatments and ultimately to find cures for all forms of childhood cancer.

Alongside this funding we will look to support initiatives which help promote earlier diagnosis from healthcare professionals so that childhood cancer can be caught earlier, which in turn will support better outcomes for the child.

Our secondary mission is to support children and their families during and after their cancer treatment by supporting welfare projects often provided by other specialist charities.

Examples include the hardship grant provided by CLIC Sargent, patient family accommodation through charities like CLIC Sargent and Ronald McDonald House Charities and the Beads of Courage UK oncology programme. We will also continue to provide family days out and expand this programme to ensure more children and their families have the opportunity to enjoy these special days out.

In 2019 we expanded our investment in our Scientific Team. This included the implementation of a new grant database which will go live in 2020. This investment will continue with the creation and implementation of our Scientific strategy due to be launched in Spring 2021. This strategy will continue to be developed and expanded in to 2021. The launch of the Scientific strategy, will create a clear path for all our supporters and fundraisers.

We have also commenced a comprehensive review of our Welfare program. This review will focus on delivering the best outcome/support for families that are affected by childhood cancer. This support can take many forms and by having a clear way forward will enable the charity to deliver on its promise to ensure we can provide better care for young cancer patients and their families.

Fundraising

Whilst our fundraising has been impacted by COVID-19, with our latest estimate being a drop in some 40% against our original budget, we have continued to work hard across all our teams to exploit existing and new fundraising opportunities.

Historically we have been very strong in raising funds and awareness from our supporters who receive our appeals through the post as well as opportunities to take part in our Grand Draws and Weekly Lottery. Our TV adverts also generate strong returns and raise awareness and are used to help us recruit new regular givers to our cause. 2020 has seen a continuation of this strong performance which has been a real positive for the Charity during these challenging times.

Sports events remain a core area of our fundraising with the key event in our calendar being the Virgin Money London Marathon and whilst 2020 has seen many event cancellations, we continue to work with our supporters who are taking part in the 'virtual' equivalents of these events whilst continuing to fundraise. We are also working closely with event organisers to ensure we maximise our participation and in turn our fundraising from events as they come back online in 2021.

As we entered 2020, we had already begun to invest in additional staff to support our growth plans into largely untested segments, such as corporate fundraising as well as philanthropy and trusts. We also began a strategic review of our community fundraising team, linking this to a drive to engage many more patient families to support our cause in the regions. Grass roots community fundraising will always be a cornerstone of any charity which touches lives across the UK.

In light of COVID-19 and its ongoing impact on the fundraising landscape, we will continue to work on our fundraising strategy and will use this as an opportunity to:

- continue the identification of new income sources with the very best talent we have whilst tapping into our network and creating development boards of highly motivated and well networked supporters.
- maximise income opportunities from current activities by enhancing our donor experience and focusing on developing longer term relationships with our supporters.
- grow our regular giving pool through powerful recruitment and retention strategies that keep the supporter engaged and connected to the outcomes of their fundraising.
- enhance our digital fundraising through all digital channels (see below).
- continue the strategic review and direction of our community team.

We also recognise that in the new and much tougher operating environment, cost control and a rigorous commercial culture / mindset, will be vital if we are to continue to produce net income which will allow us to fulfil our charitable objectives. Operational efficiency will also be key and we will continue to exploit systems and tools which allow us to spend much more time with our donors than on internal administration and processing.

We have also demonstrated our ability to operate remotely with all staff without exception, able to fully function from home, allowing us to rethink our space requirements in the future with undoubted operational savings.

Marketing and Communications

For 2020-2021 there will be a focus on increasing awareness through all our channels and in particular through media. With a new PR strategy in place, a core objective will be to significantly increase our profile as a charity broadening our current focus on research and supporter coverage to also include CEO thought leadership and policy work. Underpinning this will be a proactive journalist engagement plan.

During the pandemic in 2020 many journalists were furloughed and with a crowded media landscape gaining media coverage or journalist engagement was challenging. Our aim is to work to increase cut through in the press for 2021.

Digital marketing will see an increased focus for the charity to fully exploit the opportunities available via digital channels and to enhance the current work undertaken. The charity must enhance its online presence, raise our profile and reach new audiences to increase income. There will also be some work undertaken to understand our existing audiences better and how they are interacting with us online to ensure the charity is optimising conversions.

The COVID-19 pandemic has meant that there is increased focus on digital to deliver fundraising and marketing goals and therefore there is a requirement for more dynamic and innovative tactics to be utilised. During 2020-2021 we will invest in digital marketing and fundraising to grow our online income via regular giving, birthday giving, ecommerce and other online donations. There will be a new digital marketing strategy to underpin these objectives and drive more engagement, awareness and donations.

Operations

With the recruitment of a Chief Operating Officer a review of the Operational area has commenced. This review will include Governance, HR, IT systems, Finance Function, Database systems, and Supporter Care. Part of this review will specifically look at the IT systems along with the Fundraising and Finance databases to ensure they complement the Fundraising strategy that is currently in development. This review will continue into 2021 to ensure the Charity maximises its fundraising potential and is able to adapt effectively to the changing operational landscape.

Going Concern

The accounts are approved during a period where there is much uncertainty as a result of COVID-19. The Charity is constantly assessing the short and long term impact on its fundraising activities in the current climate.

The charity has formulated a revised budget for the current year which takes into account the uncertainty of plans to return to business as usual. In their assessment of going concern the Trustees have considered the current and developing impact on the charity as a result of the COVID19 virus. This has had a significant impact on certain activities in the current financial year including the Ball, running events and community based fundraising, which make up approximately 40% of the charity's income, but the Trustees are aware that if the current situation becomes prolonged then this may change.

The Trustees have considered scenarios including a repeat of 2020 with events being cancelled and virtual events being prevalent. There are currently significant cash balances should additional liquidity be required through this period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

The ultimate impact of COVID-19 on the charity is yet to be seen. Our cash deposits could easily be drawn down should working capital be required. Appropriate consideration of risks as part of its normal risk management processes and mitigating actions both already taken and available to be taken.

The trustees believe that although there is uncertainty regarding COVID-19 the charity remains in a strong position to use its cash deposits to take advantage of any opportunities and they are at a sufficient level to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly the Trustees consider it appropriate for the going concern basis to be adopted for these accounts.

Investments

The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.

The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore, the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.

The charity investment policy is reviewed regularly and states that the longer term funds must produce the best financial return for an acceptable risk. The fund must balance the need to support research grants with the objective for capital growth and inflation protection. The Trustees feel the 2019 performance of the investments met the objectives of the policy and recognise the opportunity to identify higher performing funds for 2020 whilst still within an acceptable risk.

The charity currently holds £11.2M of investments held for the longer term. This comprises £1.8M in an investment portfolio managed by Barclays Investment Managers and £9.4 in cash deposits. The charity also holds £4.5M in short term cash deposits.

The Trustees are keen to ensure that the cash funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2019, our grant liabilities are close to £10.6M (2018: £10.9M).

Risk and internal control

The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.

As part of the Charity's risk management process the Trustees acknowledge their responsibility for the Charity's system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity's objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

During the year, the strategic risks were reviewed and updated in order to identify the principal risks and uncertainties currently impacting the Charity along with the mitigation strategy in place to manage these risks. Areas have been identified to indicate where we should focus our risk management next year.

Principal risks and uncertainties

With the Charity being heavily reliant on mainstream fundraising income to fund charitable activity, the major risk being faced is that income falls to a level that compromises the Charity's ability to meaningfully fund future charitable activity – whilst at the same time maintaining reserves at a stable level. This risk continues to be managed by the Charity by diversifying its income streams and investing in new fundraising channels. The Charity is continuing the process of implementing 'strategic imperatives' that will guide its future vision and strategy.

The seven strategic risks that were identified during the previous years risk review have been reviewed and updated where appropriate.

- Fundraising
- Regulatory compliance
- Infrastructure & Operations
- Charitable Impact
- Profile & Brand
- Financial
- Governance

These risks have been assessed in terms of probability and impact with a mitigation strategy put in place if required. This forms part of the charity's annual risk management strategy.

The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our trading income streams to manage this risk.

At the time of writing we are in the midst of the COVID-19 Pandemic. This wasn't an identified risk during the year in review. The pandemic has had an impact on multiple areas of the organisation. Whilst the long term impact of the pandemic is still to be seen, we have reviewed our principle risks to incorporate this new risk to reach across all strategic risks that had previously been identified during the year in review.

Several plans have been implemented to mitigate this risk in the short term while longer term plans are being developed. These short term strategies include regular management meetings, continuous review of up to date income figures, engagement with all suppliers to review costs, evaluation and renegotiation of contracts where appropriate, redeployment of resources where necessary and identification, exploitation and investment of any new fundraising opportunities like digital fundraising.

There has also been a high level of Trustee engagement throughout this period. The Chair of Trustees has been in regular contact with the CEO during this time with updates to the Board. Frequent discussions of key issues amongst the Board also occurred during this time. One Trustee regularly attended the weekly update meetings attended by all staff.

Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).

The Trustees have considered and acknowledge the principles and recommendations set out in the Charity Governance Code. The Senior Leadership Team have been tasked and are in the process of reviewing the Charity's governance against the Code's best practice and identifying key areas for development. They will report back to the Board with their recommendations over the next 12 months.

Governing documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007 and 28th July 2016. On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- i) To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- ii) To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- iii) To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities.

We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 22.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of six members (2018: five). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

Trustee appointment and induction

There were two new appointments (2018: one) to the Trustee Board in January 2019. Two Trustees left the board on 2nd April 2019. In September 2020 two new Trustees were appointed and one Trustee left the Trustee Board. The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication 'The Essential Trustee: What you need to know' as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

Salary Bands and grading of job roles was introduced in 2018.

Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands will be revised as required and at least once every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiaries

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship and commercial agreements.

The trading activities generated profit for the year of £18,625 (2018: £28,051) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.

The trading subsidiary holds assets of £44,706 and liabilities of £44,606 with funds of £100 as at 31st December 2019.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a conflict of interest policy in place which accompanies the declaration of interests submissions completed by all Trustees and senior management. An internal conflict of interest register is in place which is updated when a conflict of interest has been identified and is reviewed at least annually.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2019, a total of £918,000 (2018: £3,074,748) was awarded to welfare projects.

Research grants

The Trustees aim to award an increasing proportion of the charity's grants to scientific and medical research in child and young person cancer. The charity's Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our scientific advisor panels (SAPs) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.

In 2019, a total of £3,353,277 (2018: £1,816,154) was awarded to research projects. Project funding is directed in two areas of concern:

1. Research into treatment and survival
2. Research into prevention and causes

We also fund some 5-year Post-doctoral Fellowships and Clinical PhD Studentships on these topics at leading research Institutions regarding child and young adult cancer.

REFERENCE AND ADMINISTRATION

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:

Eddie O’Gorman OBE (Founder and Chair of Trustees)
Sandra Mileham
Linda Robson
Virna Midgley
Mike England (Appointed 12th January 2019) (Left Board 2nd April 2019)
Katherine England (Appointed 12th January 2019) (Left Board 2nd April 2019)
Caroline Randerson (Appointed 8th September 2020)
Ann Amaya-Torres (Appointed 8th September 2020)
Alasdair Philips (Left Board 22nd September 2020)

Chief Executive Officer

Cliff O’Gorman (Honorary) (Appointed 6th October 2020)

Senior Management

Sophie Wiles (Chief Operating Officer) (Appointed 1st June 2020)
Gary Murphy (Head of Finance)
Zahra Scott-Gunnlaugsson (Head of Fundraising) (Appointed 1 September 2019)
Hannah Chambers (Head of Digital) (Appointed 1st March 2019)
Caroline Lane (Senior Marketing and Communications Manager) (Appointed 25th March 2020)

Previous members of the Senior Management during the year were

Fiona Judge
Fadil Dugolli
Camelia Vasilcan
Dhivya O’Connor
Jason Rigby
Ken Mackness
Pippa Gough
Shree Ranjini
Emily Roff
Samia Choudhri
Mark Bridger

Registered Charity Number
298405

Registered Company Number
4960054

Principal office
51 Great Ormond Street, London WC1N 3JQ

Solicitors
Bates Wells, 10 Queen Street Place, London, EC4R 1BEB

Auditors
Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW.

Bankers
National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ

Contact details
Children with Cancer UK
51 Great Ormond Street, London WC1N 3JQ
Tel: 020 7404 0808
Email: info@childrenwithcancer.org.uk
www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our two Scientific Advisory Panels (SAP) who freely give their time and expertise to help drive forward our fight against childhood cancer. Research into childhood cancer is a broad field and we aim to reflect the diversity of the field amongst the membership of our Treatment and Survivorship and our Causes and Prevention Panels. Some members may sit on both panels.

The Chair of the Treatment SAP is Dr Owen Williams, PhD, Reader in Cancer Biology and Head of Cancer Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust

The Chair of our Causes and Prevention SAP is Professor Geoff Pilkington, PhD CBiol FRSB FRCPATH, Professor of Cellular and Molecular Neuro-Oncology and Head of Brain Tumour Research Centre, University of Portsmouth.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.


Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 25th September 2020 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:



Eddie O'Gorman OBE
Founder and Chair of Trustees

Date: 29th October 2020

Independent Auditor's Report to the Trustees of Children with Cancer UK

Opinion

We have audited the financial statements of Children with Cancer UK for the year ended 31 December 2019 which comprise the Group Statement of Financial Activities, the Group and Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the charitable company's affairs as at 31 December 2019 and of the group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the group's or the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the course of our audit

- the information given in the trustees' report, which includes the directors' report and the strategic report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the group and the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- the parent company has not kept adequate accounting records; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 42, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group's or the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the

Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Andrew Thomas

Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor
London

Date: 30 October 2020

**Consolidated statement of financial activities for the year ended 31 December 2019
(Incorporating an income and expenditure account)**

	Note	Total restricted funds £	Total unrestricted funds £	Total 2019 £	Total 2018 £
Income from:					
Donations and legacies	4	240,594	16,137,595	16,378,190	15,499,849
Other trading activities	4	-	828,225	828,225	1,137,671
Income from investments		-	82,636	82,636	163,574
Other income		-	41,375	41,375	14,745
Total Income	19	240,594	17,089,831	17,330,425	16,815,839
Expenditure on:					
Raising funds	6	-	3,956,547	3,956,547	3,381,462
Charitable activities	6, 8	621,947	12,238,453	12,860,400	12,675,665
Total Expenditure	6,16	621,947	16,195,000	16,816,947	16,057,127
Net change in investments	12	-	216,320	216,320	(131,398)
Net income/(expenditure)		(381,353)	1,111,150	729,797	627,314
Transfers between funds	19	(155,781)	155,781	-	-
Net movement in funds		(537,134)	1,266,931	729,797	627,314
Reconciliation of funds:					
Total funds brought forward		1,064,478	9,107,144	10,171,622	9,544,308
Total funds carried forward	19	527,344	10,374,075	10,901,419	10,171,622

The comparative figures for each fund are shown in note 3 to the financial statements.

Balance sheet as at 31 December 2019


Company Number: 4960054

	Note	2019		2018	
		Group	Charity	Group	Charity
		£	£	£	£
Fixed assets					
Investments	12	11,157,521	11,157,621	12,881,039	12,881,139
		11,157,521	11,157,621	12,881,039	12,881,139
Current assets					
Debtors and prepayments	14	4,272,145	4,299,474	3,435,939	3,456,952
Cash deposits		4,445,032	4,445,032	4,427,661	4,427,661
Cash at bank and in hand		2,246,853	2,215,824	1,563,643	1,510,778
		10,964,030	10,960,330	9,427,243	9,395,391
Creditors: amounts falling due within one year					
Grants	15,16	(3,850,858)	(3,850,858)	(4,950,499)	(4,950,499)
Other	16	(692,634)	(689,034)	(1,255,739)	(1,252,039)
Net current assets	18	6,420,538	6,420,438	3,221,005	3,192,853
Total assets less current liabilities		17,578,059	17,578,059	16,102,044	16,073,992
Creditors: amounts falling due after more than one year					
Grants	15	(6,676,640)	(6,676,640)	(5,930,422)	(5,930,422)
Net assets		10,901,419	10,901,419	10,171,622	10,143,570
Represented by:					
Unrestricted funds		10,374,075	10,374,075	9,107,144	9,079,092
Restricted funds		527,344	527,344	1,064,478	1,064,478
	18,19	10,901,419	10,901,419	10,171,622	10,143,570

The net income for the financial year dealt within the financial statements of the parent charitable company was £767,274 (2018: £599,263).

The notes on pages 49 to 68 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 29th October 2020.



Eddie O'Gorman OBE
Trustee



Sandra Mileham
Trustee

Consolidated cash flow statement for the year ended 31 December 2019

		2019		2018
		£		£
Cash flows from operating activities:				
Net cash provided by operating activities	a)	(1,316,750)		(1,203,328)
Cash flows from investing activities:				
Dividends and interest from investments		82,636		163,574
Net additions/(disposals) in the year		(1,678)		11,992
Net cash provided by investing activities		80,958		175,566
Change in cash and cash equivalents in the reporting period		(1,235,792)		(1,027,762)
Cash and cash equivalents at the beginning of the reporting period	b)	17,281,531		18,309,293
Cash and cash equivalents at the end of the reporting period	b)	16,045,738		17,281,531
Notes to the Cash flow Statement				
a) Reconciliation of net (expenditure) to net cash flow from operating activities				
		2019		2018
		£		£
Net (expenditure)/income for the reporting period		729,797		627,314
Adjustments for:				
Dividends, interest and rents from investments		(82,636)		(163,574)
Investment Manager Fees		5,141		12,780
Net Change in investments		(216,320)		131,398
Decrease / (increase) in debtors		(836,206)		(421,166)
(Decrease) / increase in creditors		(916,526)		(1,390,080)
Net cash provided by (used in) operating activities		(1,316,750)		(1,203,328)
b) Analysis of cash and cash equivalents				
		1 January 2019	Cashflow	31 December 2019
		£	£	£
Cash at bank and in hand		1,563,643	683,210	2,246,853
Cash held as short term investments		4,427,661	17,371	4,445,032
Cash held as long term investments		11,290,227	(1,936,374)	9,353,853
		17,281,531	(1,235,792)	16,045,738

Notes to the financial statements for the year ended 31 December 2019

1. Charity information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 51 Great Ormond Street, London WC1N 3JQ. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.

2. Accounting policies

(a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

(b) Preparation of the accounts on a going concern basis

In their assessment of going concern the Trustees have considered the current and developing impact on the charity as a result of the COVID19 virus. This has had a significant impact on certain activities in the current financial year including the Ball, running events and community based fundraising, which make up approximately 40% of the charity's income, but the Trustees are aware that if the current situation becomes prolonged then this may change. The Trustees have considered scenarios including a repeat of 2020 with events being cancelled and virtual events being prevalent. There are currently significant cash balances should additional liquidity be required through this period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

Accordingly, the Trustees believe the Charity's financial resources are sufficient to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements and have therefore prepared the financial statements on the going concern basis.

(c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

(d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

(e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

(f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

(g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

(h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

(i) Tangible fixed assets

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

(j) Pension scheme

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. From January 2019 to March 2019, the charity made a contribution of 8% (2018: 8%) of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. In April 2019 this was increased to 9%. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

(k) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

(l) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

(m) Private Medical Insurance

Since October 2017, permanent employees are entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2019, the charity paid a premium based on the employee's ages per month to all employees after serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.

3. Consolidated statement of financial activities for the year ended 31 December 2018

	Total restricted funds £	Total unrestricted funds £	Total 2018 £
Income from:			
Donations and legacies	1,174,990	14,324,859	15,499,849
Other trading activities	-	1,137,671	1,137,671
Income from investments	-	163,574	163,574
Other income	-	14,745	14,745
Total Income	1,174,990	15,640,849	16,815,839
Expenditure on:			
Raising funds	-	3,381,462	3,381,462
Charitable activities	-	12,675,665	12,675,665
Total Expenditure	-	16,057,127	16,057,127
Net change in investments	-	(131,398)	(131,398)
Net (expenditure)/income	1,174,990	(547,676)	627,314
Transfers between funds	(110,512)	110,512	-
Net movement in funds	1,064,478	(437,164)	627,314
Reconciliation of funds:			
Total funds brought forward	-	9,544,308	9,544,308
Total funds carried forward	1,064,478	9,107,144	10,171,622

4. Income

	2019 £	2018 £
Donations and legacies		
Appeals and associated donations	4,357,740	3,674,408
Committed giving	2,080,202	1,845,286
Community fundraising	1,813,260	1,356,016
Corporate and trust donations	2,163,789	1,046,615
Legacies (see contingent asset below)	1,396,017	1,507,445
Sports events	4,549,199	4,856,927
Transfer of funds (See below)	(7,177)	1,064,478
	16,353,030	15,351,175
Scratch cards (see scratch card income below)	25,160	148,674
	16,378,190	15,499,849
Other trading activities		
Events	828,225	1,137,671
	828,225	1,137,671

Included in Donations and legacies is a (£7,177) adjustment for £1,064,748 of funds received in 2018 which relates to the transfer of funds from Children's Leukaemia Trust (charity number 1000341). This is the difference of expected and actual funds received. See Note 19.

Contingent asset – legacy income

As at 31 December 2019, the charity had been notified of a further 12 residuary and 5 pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £703,852 which has not been accrued.

Scratch card income

The scratch card income relates to the sale of gambling products as part of a corporate partnership with the Gala Coral Group Ltd. As part of the agreement, the charity receives 20% of the sales proceeds of the scratch card. However, as the product was launched under the charity's Gambling Commission license, the charity has recognised 100% of the sales proceeds as income and 80% as expenditure.

5. Lottery income

As part of the charity's Gambling Commission License (Non Remote License - 000-004700-N-306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2019:

	Ticket sales £
Weekly Lottery	465,524
Christmas Raffle (draw 8 th February 2019)	504,499
Spring Raffle (draw 7 th June 2019)	415,175
Summer Raffle (draw 20 th September 2019)	392,884
Total	1,778,082

As the Christmas raffle spans two accounting periods, £130,550 was received during 2019 and £373,949 during 2018. All other ticket sales were received during 2019 only. All ticket sales have been included within the total income for 2019 and 2018.

As explained in Note 4, the charity operates a scratch card with Gala Coral Group Ltd acting as the external lottery manager. Six scratch cards were launched on 21st October 2014 with an expiry date of 31st March 2016 and a further two were made available on 3rd July and 14th August 2015 expiring on 31st December 2016. Six more scratch cards were made available during 2016 with two expiring on 30th June 2017, one expiring on 31st January 2018 and the remaining three expiring on 31st March 2018. A final three scratch cards were made available on 1st April 2018 with one expiring on 31st March 2019 and the final scratch card expiring on 30th June 2019. The total sales of these scratch cards amounted to £7,550,358.

These sales have been included within the total income for 2014 to 2019 as follows:

	2019 £	2018 £	2017 £	2016 £	2015 £	2014 £	Total £
Gross Sales	32,886	175,094	667,971	1,840,993	4,215,340	618,074	7,550,358
Prizes and Management Fee	26,288	140,078	534,395	1,472,794	3,372,272	494,459	6,040,286
Net Sales	6,598	35,016	133,576	368,199	843,068	123,615	1,510,072

During the year three Scratchcards that were made available during 2018 expired with total sales of £98,653 as follows:

Scratchcard Name	Value	Total Sales	Start Date	Expiry Date
Winner's Post	£2	59,808	20/04/2018	31/03/2019
It Could Be Shoe	£1	52,648	20/04/2018	30/06/2019
Scratch to Score	£1	46,005	20/04/2018	30/06/2019
Total		158,461		

The following summarises the expired scratch cards during the period since the scratch card sales were launched in October 2014.

	2019 £	2018 £	2017 £	2016 £	2015 £	2014 £	Total £
Gross Sales	158,461	1,111,493	849,571	597,419	4,215,340	618,074	7,550,358
Prizes and Management Fee	126,769	889,195	679,657	477,935	3,372,272	494,459	6,040,286
Net Sales	31,692	222,298	169,914	119,484	843,068	123,615	1,510,072

In line with the requirements under Social responsibility code provision 4.3.1 of the License Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2019.

Lottery type	Lottery Name	Percentage proceeds returned to Charity %
Managed directly by Children With Cancer UK	Linda's Lottery – Weekly Draw	55%
Managed directly by Children With Cancer UK	Children with Cancer Grand Draw	71%
Managed by Coral	Scratch cards	20%
Total		67%

6. Total expenditure

	Staff Costs £	Direct Costs £	Support and Governance £	2019 Total £	2018 Total (Restated*) £
Expenditure on Raising funds					
Fundraising Costs	772,912	2,656,151	527,484	3,956,547	3,381,462
Expenditure on Charitable activities					
Research into Prevention & Causes	271,175	3,666,016	168,648	4,105,839	1,502,502
Research into Treatment	292,385	1,527,405	166,107	1,985,897	3,176,171
Welfare	346,718	2,010,255	248,788	2,605,761	4,942,223
Education	841,904	2,833,049	487,950	4,162,903	3,054,768
	1,752,182	10,036,725	1,071,493	12,860,400	12,675,664
	2,525,094	12,692,876	1,598,977	16,816,946	16,057,126

	Staff Costs £	Direct Costs £	Support and Governance £	2018 Total* £
Expenditure on Raising funds				
Fundraising Costs	574,282	2,429,983	377,197	3,381,462
Expenditure on Charitable activities				
Research into Prevention & Causes	204,134	1,183,279	115,090	1,502,503
Research into Treatment	210,379	2,851,725	114,067	3,176,171
Welfare	254,986	4,532,031	115,206	4,942,223
Education	599,066	2,170,853	284,849	3,054,768
	1,268,565	10,737,888	669,212	12,675,664
	1,842,847	13,167,871	1,046,409	16,057,126

*2018 Total has been restated to align with new presentation of disclosure of Total Expenditure.

7. Support costs

Support costs are split as follows:

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2019 Total £
Expenditure on Raising funds						
Fundraising Costs	56,035	146,794	179,023	77,519	68,113	527,484
Expenditure on Charitable activities						
Research into Prevention & Causes	19,162	38,468	61,218	26,508	23,292	168,648
Research into Treatment	18,873	37,889	60,295	26,109	22,941	166,107
Welfare	28,267	56,748	90,307	39,105	34,360	248,787
Education	55,440	111,300	177,123	76,697	67,390	487,950
	121,742	244,405	388,943	168,419	147,983	1,071,492
	177,777	391,199	567,966	245,938	216,096	1,598,976

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2018 Total £
Expenditure on Raising funds						
Fundraising Costs	57,013	119,195	101,644	50,868	48,477	377,197
Expenditure on Charitable activities						
Research into Prevention & Causes	19,774	25,605	35,254	17,643	16,814	115,090
Research into Treatment	19,353	26,489	34,503	17,267	16,455	114,067
Welfare	26,333	36,042	46,947	23,494	22,390	155,206
Education	48,328	66,148	86,161	43,119	41,093	284,849
	113,788	154,284	202,865	101,523	96,752	669,212
	170,801	273,479	304,509	152,391	145,229	1,046,409

*2018 Total has been restated to align with new presentation of disclosure of Support Costs.

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.

8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2019 Total £	2018 Total £
Research into Prevention & Causes	1,218,255	2,718,936	168,648	4,105,839	1,502,502
Research into Treatment	1,185,449	634,341	166,107	1,985,897	3,176,171
Welfare	1,438,974	918,000	248,788	2,605,761	4,942,223
Education	3,656,553	18,400	487,950	4,162,903	3,054,769
	7,449,231	4,289,677	1,071,492	12,860,390	12,675,665
	=====	=====	=====	=====	=====

9. Auditor Costs

	Statutory Audit Fee £	Other Financial Services £	2019 Total £
Children with Cancer UK	30,700	1,428	32,128
Helping Children with Cancer Ltd	3,600	-	3,600
	34,300	1,428	35,728
	=====	=====	=====

Other Financial Services Includes £238 of irrecoverable VAT.

	Statutory Audit Fee £	Other Financial Services £	2018 Total £
Children with Cancer UK	29,700	4,968	34,668
Helping Children with Cancer Ltd	3,600	-	3,600
	33,300	4,948	38,268
	=====	=====	=====

Other Financial Services Includes £838 of irrecoverable VAT.

10. Staff costs

	2019 £	2018 £
Salaries and wages	2,104,647	1,544,840
National Insurance	218,778	160,786
Pension	190,084	125,235
Private Medical Insurance	11,585	11,986
	2,525,094	1,842,847
	=====	=====

During 2019, the following employees were paid in the following salary ranges.

Salary Range	2019 £	2018 £
£60,000 - £70,000	1	2
£70,000 - £80,000	0	2
£90,000 - £100,000	0	1
£170,000 - £180,000	1	0

There have been 8 (2018: 9) positions that have formed part of the senior leadership team during 2019. The total remuneration including pension contributions for these employees amounts to £807,307 (2018: £628,881).

In addition to the management section on page 37, a previous employee who left the organisation in September 2018 that is connected to a Trustee was paid £8,700 pension contributions relating to employment from 2013 – 2015 that were due but had not been paid at the time (2018: £72,539 gross salary and £3,963 pension contributions). There is no interdependence between the Trustee and the connected person.

During the year there were two (2018: three) redundancy, termination or settlement payments made totalling £97,095 (2018: £45,096)

The average weekly number of contracted employees during the year was as follows:

	2019	2018
	No.	No.
Charitable Activities	4	3
Raising Funds	39	29
Support, Governance, Operations and Administration	13	11
	<u>56</u>	<u>43</u>
	=====	=====

11. Results of the parent charity

	2019	2018
	£	£
Total income	17,354,706	16,775,497
Total expenditure	(16,813,313)	(16,044,836)
Unrealised gains / (Loses)	216,320	(131,398)
Net Income	<u>757,712</u>	<u>599,263</u>
	=====	=====

12. Investments

	2019 £	2018 £
Listed investments (see below)	1,803,668	1,590,812
Cash deposits	9,353,853	11,290,227
	11,157,521	12,881,039
	=====	=====
Market value of listed investments at 1 Jan	1,590,812	1,746,983
Additions to investment portfolio	5,389	1,840,720
Disposals to investment portfolio	(3,712)	(1,852,713)
Investment manager fees	(5,141)	(12,780)
Net Investment gain/(loss)	216,320	(131,398)
	1,803,668	1,590,812
	=====	=====
Listed Investments comprise the following:		
Cash and short maturity bonds	5,246	4,998
Multi class and other investments	1,798,422	1,585,814
	1,803,668	1,590,812
	=====	=====

Total Investments are listed in:		
United Kingdom	226,360	1,118,341
Overseas	1,577,308	472,471
	1,803,668	1,590,812
	=====	=====

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.

The income and expenditure for the year ended 31 December 2019 is as follows:

	2019 £	2018 £
Income	30,742	40,342
Administrative expenses	(12,117)	(12,291)
	18,625	28,051
	=====	=====

The balance sheet for the subsidiary as at 31 December 2019 is as follows:

	2019 £	2018 £
Assets	44,706	81,382
Liabilities	(44,606)	(53,231)
	100	28,151
	=====	=====

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

13. Trustees' emoluments

The Trustees received no remuneration or reimbursement of expenses during the year (2018 Nil).

14. Debtors

	2019 Group £	2019 Charity £	2018 Group £	2018 Charity £
Amounts due from subsidiary undertakings	-	41,006	-	49,531
Other debtors	1,513,009	1,516,009	916,556	916,556
Accrued income	986,757	973,080	776,926	748,408
Prepayments	1,772,379	1,772,379	1,742,457	1,742,457
	4,272,145	4,299,474	3,435,939	3,456,952
	=====	=====	=====	=====

15. Grants to third parties

	2019 £	2018 £
Outstanding liabilities at the start of the year	10,880,921	12,811,232
Aw arded during the year (note 21):		
Research into prevention and causes	2,718,936	97,878
Research into treatment	634,341	1,718,276
Welfare	918,000	3,074,748
Raising aw areness	18,400	-
	4,289,677	4,890,902
Under-spends on previous grant aw ards	(250,000)	(139,453)
Paid during the year	(4,393,100)	(6,681,760)
Outstanding liabilities at the end of the year	10,527,498	10,880,921
	=====	=====
Grants falling due w ithin one year	3,850,858	4,950,499
Grants falling due after more than one year	6,676,640	5,930,422
	10,527,498	10,880,921
	=====	=====

16. Creditors: amounts falling due within one year

	2019 Group £	2019 Charity £	2018 Group £	2018 Charity £
Accruals and deferred income	640,720	637,120	1,209,914	1,206,214
Taxes and social security	51,914	51,914	45,825	45,825
	692,634	689,034	1,255,739	1,252,039
Grants payable	3,850,858	3,850,858	4,950,499	4,950,499
	4,543,492	4,539,892	6,206,238	6,202,538
	=====	=====	=====	=====

17. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2019 Group £	2019 Charity £	2018 Group £	2018 Charity £
Balance as at 1 January 2019	53,020	53,020	55,105	55,105
Amount released to income	(53,020)	(53,020)	(55,105)	(55,105)
Amount deferred in year	51,599	51,599	53,020	53,020
Balance as at 31 December 2019	51,599	51,599	53,020	53,020

18. Analysis of net assets between funds

As at 31 December 2019	2019 Group Restricted funds £	2019 Group Unrestricted funds £	2019 Group Total funds £	2018 Group Total funds £
Fixed assets	-	11,157,521	11,157,521	12,881,039
Net current assets	527,344	5,893,194	6,420,538	3,221,005
Creditors falling due after more than one year	-	(6,676,640)	(6,676,640)	(5,930,422)
Net assets at the end of the year	527,344	10,374,075	10,901,419	10,171,622

As at 31 December 2018	2018 Group Restricted funds £	2018 Group Unrestricted funds £	2018 Group Total funds £	2017 Group Total funds £
Fixed assets	-	12,881,039	12,881,039	14,581,097
Net current assets	1,064,478	2,156,527	3,221,005	905,283
Creditors falling due after more than one year	-	(5,930,422)	(5,930,422)	(5,942,072)
Net assets at the end of the year	1,064,478	9,107,144	10,171,622	9,544,308

19. Statement of funds

Year ended 31 December 2019	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
Discovery of biomarkers and new therapeutic targets for chemotherapy associated neurotoxicity	-	3,000	-	(3,000)	-
BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma Biology Consortium	-	300	-	(300)	-
Advanced magnetic resonance imaging techniques for in vivo assessment of tumour heterogeneity, risk factor, and treatment response in paediatric cancer	-	8,300	-	(8,300)	-
Evaluation of B7H3 as a novel target for immunotherapy in childhood cancer	-	2,560	-	(2,560)	-
Dr Karin Straathof, UCL Institute of Child Health, Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma	-	9,500	-	(9,500)	-
Professor Christine Harrison, Northern Institute for Cancer Research, New castle University, Sequencing the unsequenceable: development of ground-breaking technologies to investigate the role of complex genomic sequences in childhood cancer	-	56,108	-	(56,108)	-
Helen E Bryant, University of Sheffield, Novel therapies for MYCN-amplified neuroblastoma	-	500	-	(500)	-
Dr Amin Hajitou, Imperial College London, Investigation of a harmless prokaryotic virus for intravenous targeting delivery of therapeutic nucleic acids to DIPG	-	25,000	-	(25,000)	-
Professor Louis Chesler, Institute for Cancer Research- Individualising Management of Paediatric Cancer Treatment - IMPACT	-	49,188	-	(49,188)	-
Professor Sibylle Mitnacht, UCL Cancer Institute- Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma	-	750	-	(750)	-
Dr John Bithell, University of Oxford- Preservation and analysis of pathology records and family histories of children with cancer	-	500	-	(500)	-
Clinical PhD Studentship: Markers of Hypothalamic Dysfunction in Children with Hypothalamo-Pituitary-Axis Tumours (HPAT) or Pituitary Maldevelopment	-	75	-	(75)	-
Osteosarcoma Symposium	-	30,000	(30,000)	-	-
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia	-	11,753	(11,753)	-	-
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	50,238	(50,238)	-	-
Children's Leukaemia Trust. Restricted for research into and training for Leukaemia and Lymphoma in children	1,064,478	(7,177)	(529,957)	-	527,344
Total Restricted funds	1,064,478	240,594	(621,947)	(155,781)	527,344
Unrestricted funds	9,107,144	17,089,346	(16,195,000)	372,449	10,373,939
Total Unrestricted funds	9,107,144	17,089,346	(16,195,000)	372,449	10,373,939
Total funds	10,171,622	17,329,940	(16,816,946)	216,668	10,901,283

Note

The restricted funds comprise donations that were to be spent on specific causes and projects. Following the dissolution of Children's Leukaemia Trust (charity number 1000341) we benefited from a one off donation of £1,064,478 in 2018, which was restricted to research into and training for Leukaemia and Lymphoma in children. £529,957 of this fund has been allocated to the following projects, leaving £527,344 to be carried forward.

Children's Leukaemia Trust restricted donation allocation	Research into prevention and causes £	Research into treatment £	Total £
Safety enhanced CART cell therapy for paediatric AML	-	250,000	250,000
Energy supplements protect pancreas from side effects of Asparaginase	50,000	-	50,000
Exploring the role of the tumour suppressor ATRX in Leukaemia	-	50,000	50,000
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia	-	26,000	26,000
CCL17 and the early diagnosis of classical Hodgkin lymphoma – a feasibility study in the primary care setting	49,780	-	49,780
Professor Pamela Kearns. Programme grant: UK ALL 2011	-	104,177	104,177
Total funds	99,780	430,177	529,957

All other restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

Year ended 31 December 2018	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
Dr Kathleen Birley, Institute of Child Health, University College London. Evaluation of B7H3 as a novel target for immunotherapy in childhood cancer	-	40,255	-	(40,255)	-
Professor Richard Grundy. BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma Biology Consortium	-	2,435	-	(2,435)	-
Dr Ian Hampson, University of Manchester. Identification of infections which may play a role in the aetiology of childhood acute lymphoblastic leukaemia (ALL)	-	5,000	-	(5,000)	-
Professor Christine Harrison, Northern Institute for Cancer Research, Newcastle University, Sequencing the unsequenceable: development of ground-breaking technologies to investigate the role of complex genomic sequences in childhood cancer	-	5,858	-	(5,858)	-
Professor David Walker, University of Nottingham, Children's Brain Tumour Drug Delivery Consortium	-	307	-	(307)	-
Professor Louis Chesler, Institute of Cancer Research, Individualising Management of Paediatric Cancer Treatment - IMPACT	-	53,286	-	(53,286)	-
Professor Robert Mairs, University of Glasgow - Two radiopharmaceuticals for treatment of neuroblastoma	-	3,172	-	(3,172)	-
Professor Sibylle Mitnacht, UCL Cancer Institute- Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma	-	200	-	(200)	-
Children's Leukaemia Trust. Restricted for research into and training for Leukaemia and Lymphoma in children	-	1,064,478	-	-	1,064,478
Total Restricted funds	-	1,174,991	-	(110,513)	1,064,478
Unrestricted funds	9,544,308	15,640,849	(16,057,127)	110,512	9,238,542
Investment Gains / Losses	-	-	-	(131,398)	(131,398)
Total Unrestricted funds	9,544,308	15,640,849	(16,057,127)	(20,886)	9,107,144
Total funds	9,544,308	16,815,840	(16,057,127)	(131,398)	10,171,622

20. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

A management fee of £5,000 (2018: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £3,484 (2018: £3,558) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2019, £0 (2018: Nil) was owed to the trading subsidiary from the charity and, conversely, £41,006 (2018: £49,531) owed to the charity from the trading subsidiary.

21. Financial Instruments

The financial statements include the following in respect of items:

	2019 £	2018 £
Financial assets measured at fair value	1,803,668	1,590,812

	2019 £	2018 £
The entity's income, expense, gains and losses in respect of financial instruments are summarised below:		
Total interest income for financial assets held at fair value	82,499	163,574

22. Grants to third parties

	Research into prevention and causes 2019 £	Research into treatment 2019 £	Education 2019 £	Welfare 2019 £	Total 2019 £
Does maternal ambient air exposure to traffic-related particulate matter induce carcinogenic responses in the foetus?	350,000				350,000
CLIC Sargent - Grants Programme				350,000	350,000
Assessment of potential health impacts from transplacental exposure to carcinogenic air pollutants.	349,833				349,833
Cancer risk in childhood cancer survivors (CRICCS): understanding the causes to target prevention	349,400				349,400
Investigating metabolic mechanisms driving childhood brain cancer	347,609				347,609
Timing and Duration of Breastfeeding and Childhood Brain Tumor Risk	332,838				332,838
Folate metabolism and risk of childhood leukemia: a biomarker study	299,944				299,944
Ronald McDonald House Charities - Day Room at Ronald McDonald House Oxford				288,000	288,000
Beads of Courage				280,000	280,000
Safety enhanced CAR T cell therapy for paediatric AML		250,000			250,000
Motorized Traffic and Risk of Childhood Leukaemia	214,500				214,500
Early exposure to radio-frequency electromagnetic fields and cancer: complete evaluation of the Ramazzini Institute long-term carcinogenicity bioassays on Sprague-Dawley rats	180,060				180,060
Accelerating personalised treatment for children with neuroblastoma with MRI biomarkers		134,346			134,346
Interaction between ionising radiation and genetic susceptibility in the aetiology of childhood acute lymphoblastic leukaemia	122,208				122,208
Molecular tracking of treatment response in paediatric AML		116,010			116,010
Conference and meeting grants - see below	14,764	48,169	18,400		81,333
Energy supplements protect pancreas from side effects of Asparaginase	50,000				50,000
Exploring the role of the tumour suppressor ATRX in Leukaemia		50,000			50,000
CCL17 and the early diagnosis of classical Hodgkin lymphoma – a feasibility study in the primary care setting	49,780				49,780
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia		26,000			26,000
Exploratory collaborative grant: environmental causes of childhood leukaemia-associated chromosomal translocations	25,000				25,000
Urgent support requested for continuing work on rat exposures to electromagnetic fields	25,000				25,000
Enhancer of Zest homolog 2 (EZH2) as a therapeutic target in rhabdomyosarcomas		9,816			9,816
Low Level Ionising Radiation Exposure and Child Cancer and Mortality	8,000				8,000
Total grants to third parties	2,718,936	634,341	18,400	918,000	4,289,677

Various conference and meeting grants	Research into prevention and causes 2019	Research into treatment 2019	Education	Welfare 2019	Total 2019
	£	£	£	£	£
Osteosarcoma Symposium		30,000			30,000
Radiation Health 2019 International Conference	10,000				10,000
Solving Kids Cancer Neuroblastoma Parent Education Conference			10,000		10,000
British Neuro Oncology Society Meeting 2019			8,400		8,400
Travel costs to SMPaeds Launch Meeting		5,000			5,000
Innovative Therapies for Children with Cancer Biology Group Meeting 2019		4,000			4,000
World-wide trends in Survival from common childhood brain tumours: a systematic review		1,965			1,965
Honorarium Payment	1,737				1,737
Cost of live streaming of Paediatric Brain Tumour Symposium		1,656			1,656
Global trends in survival from brain tumours in adolescents and young adults		1,590			1,590
Honorarium Payment	1,527				1,527
Pan Care Education Day		1,508			1,508
Honorarium Payment	1,500				1,500
European Soft Tissue Sarcoma Group meeting		1,000			1,000
SIOP-Europe Brain Tumor Group Annual Meeting 2019		750			750
Travel Grant to SIOP-Europe Brain Tumour Group Annual Meeting		700			700
Total conference and meeting grants	14,764	48,169	18,400	-	81,333

23. Post Balance Sheet Event

As explained more fully in the Trustee Report, Covid-19 has had a material adverse effect upon the operational and financial position of the Charity as it has upon very many organisations around the World. The Charity has cancelled its main events including the Ball for 2020 and running events with the 2020 London Marathon being postponed and subsequently local virtual marathons taking place in October which has resulted in a reduction to income from this source. The expectation at the date of approval of these financial statements is that the year ending 31 December 2020 will consequently show a deficit on the Statement of Financial Activities with some recovery from that position in the following year.



Every day more than 12 children and young people are diagnosed with cancer in the UK.



8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.



We need to develop safer, kinder and more effective cancer therapies for children, with fewer toxic side effects. We strive to ensure that we are doing everything we can to improve the lives of children with cancer.



We fund Research



We fund Welfare



We raise Awareness

Children with Cancer UK
Registered Office
51 Great Ormond Street
London
WC1N 3JQ